Eli Lilly and Co

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: 43K

Market Cap: $859.4B

Website

Introduction: Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products consist of diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly in May 1876 and is headquartered in Indianapolis, IN.

Clinical Trials

A Study of LY3361237 in Participants With Systemic Lupus Erythematosus

Phase 1

Completed

Conditions: Lupus Erythematosus, Systemic

Interventions: Drug: LY3361237
Drug: Placebo

First Posted Date: 2019-05-01

Last Posted Date: 2021-03-04

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 28

Registration Number: NCT03933943

Locations: 🇺🇸
West Tennessee Research Institute, Jackson, Tennessee, United States
🇺🇸
Accurate Clinical Management LLC - Katy, Houston, Texas, United States
🇺🇸
Altoona Center For Clinical Research, Duncansville, Pennsylvania, United States

and more 5 locations

A Study of LY3502970 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Placebo
Drug: LY3502970
Drug: Atorvastatin
Drug: Simvastatin
Drug: Midazolam

First Posted Date: 2019-04-29

Last Posted Date: 2020-11-18

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 133

Registration Number: NCT03929744

Locations: 🇺🇸
Covance Dallas, Dallas, Texas, United States

A Study of LY3305677 in Participants With Type 2 Diabetes

Phase 1

Completed

Conditions: Diabetes Mellitus, Type 2

Interventions: Drug: Placebo
Drug: LY3305677

First Posted Date: 2019-04-26

Last Posted Date: 2021-07-19

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 24

Registration Number: NCT03928379

Locations: 🇩🇪
Profil Institut für Stoffwechselforschung, Neuss, Nordrhein-Westfalen, Germany

A Study of Mirikizumab (LY3074828) in Participants With Crohn's Disease

Phase 3

Completed

Conditions: Crohn's Disease

Interventions: Drug: Placebo
Drug: Mirikizumab
Drug: Ustekinumab

First Posted Date: 2019-04-24

Last Posted Date: 2024-12-27

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 1158

Registration Number: NCT03926130

Locations: 🇺🇸
University Hospitals Cleveland Medical Center, Cleveland, Ohio, United States
🇺🇸
Digestive Health Specialists, Tupelo, Mississippi, United States
🇺🇸
GastroIntestinal Biosciences Clinical Trials, Los Angeles, California, United States

and more 568 locations

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis

Phase 4

Active, not recruiting

Conditions: Rheumatoid Arthritis

Interventions: Drug: TNF Inhibitor
Drug: Baricitinib

First Posted Date: 2019-04-16

Last Posted Date: 2024-12-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 2600

Registration Number: NCT03915964

Locations: 🇺🇸
Medvin Clinical Research - Covina, Covina, California, United States
🇺🇸
Robin K. Dore MD, Inc, Tustin, California, United States
🇺🇸
Medvin Clinical Research - Whittier, Whittier, California, United States

and more 251 locations

A Study of Different Injectable Formulations of LY3375880 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3375880
Drug: Buffer Matrix (No LY3375880)
Device: Autoinjector (AI)
Device: Manual Syringe

First Posted Date: 2019-04-12

Last Posted Date: 2019-10-11

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 83

Registration Number: NCT03913260

Locations: 🇺🇸
Covance, Dallas, Texas, United States
🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

A Study of Baricitinib (LY3009104) in Adults With Severe or Very Severe Alopecia Areata

Phase 3

Active, not recruiting

Conditions: Alopecia Areata

Interventions: Drug: Baricitinib
Drug: Placebo

First Posted Date: 2019-04-02

Last Posted Date: 2024-10-17

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 546

Registration Number: NCT03899259

Locations: 🇦🇷
Centro de Investigaciones Médicas Tucuman, SAN M. DE Tucuman, Tucuman, Argentina
🇧🇷
Hospital de Clínicas Da Universidade Estadual de Campinas, Campinas, Sao Paulo, Brazil
🇧🇷
Faculdade de Medicina do ABC, Santo André, Sao Paulo, Brazil

and more 93 locations

A Study of LY3295668 Erbumine in Participants With Extensive-stage Small-Cell Lung Cancer

Phase 1

Completed

Conditions: Small Cell Lung Cancer

Interventions: Drug: LY3295668 Erbumine

First Posted Date: 2019-04-02

Last Posted Date: 2021-08-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 48

Registration Number: NCT03898791

Locations: 🇺🇸
University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, United States
🇺🇸
Highlands Oncology Group, Fayetteville, Arkansas, United States
🇧🇪
Universitair Ziekenhuis Gent, Gent, Belgium

and more 37 locations

A Study of an Automated Insulin Delivery System in Adult Participants With Type 1 Diabetes

Not Applicable

Completed

Conditions: Type 1 Diabetes Mellitus

Interventions: Device: AID System
Drug: Insulin Lispro

First Posted Date: 2019-03-26

Last Posted Date: 2019-06-05

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 10

Registration Number: NCT03890003

Locations: 🇺🇸
Sansum Diabetes Research Institute, Santa Barbara, California, United States

A Study of Injections of LY3074828 in Healthy Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: LY3074828
Device: Pre-filled syringe (PFS)
Device: Autoinjector (AI)

First Posted Date: 2019-03-22

Last Posted Date: 2024-02-20

Lead Sponsor: Eli Lilly and Company

Target Recruit Count: 66

Registration Number: NCT03886948

Locations: 🇺🇸
Covance Clinical Research Inc, Daytona Beach, Florida, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy